A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study - Wikidata - wikimedia - TriplyDB

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study

http://www.wikidata.org/entity/Q36980484

about

The estrogen receptor joins other cancer biomarkers as a predictor of outcome Past, present, and future of hormonal therapy in recurrent endometrial cancer Endometrial Carcinoma: Role of Current and Emerging Biomarkers in Resolving Persistent Clinical Dilemmas A phase II trial of brivanib in recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study.Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N A phase II evaluation of cediranib in the treatment of recurrent or persistent endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.A phase II trial of trebananib (AMG 386; IND#111071), a selective angiopoietin 1/2 neutralizing peptibody, in patients with persistent/recurrent carcinoma of the endometrium: An NRG/Gynecologic Oncology Group trial.Recent Advances in Endometrial Cancer.Comprehensive profiling of EGFR/HER receptors for personalized treatment of gynecologic cancers.Recent and current Phase II clinical trials in endometrial cancer: review of the state of art.Update on prognostic markers for endometrial cancer.Emerging drugs for endometrial cancer.An update on the current pharmacotherapy for endometrial cancer.New Targeted Agents in Endometrial Cancer: Are We Really Making Progress?Chemotherapy for Endometrial Cancer in Adjuvant and Advanced Disease Settings Endometrial Carcinoma: Specific Targeted Pathways.New therapies for advanced, recurrent, and metastatic endometrial cancers.Clinical trials in gynecologic oncology: Past, present, and future.Cancer of the corpus uteri.Targeted therapy in gynecologic cancers: Ready for prime time?Significance of calreticulin as a prognostic factor in endometrial cancer.

P2860

Q26865554-BBB3BAFF-2F49-4E61-ABAA-98B2F22A84C1 Q26993208-C51AFB7F-9E27-40C9-8CC8-0EE95EDD633E Q28074769-AE437A6C-B63A-458A-948D-B4BC88A07396 Q34781699-A3E5BA00-E9EE-4494-BE6F-C44F436D7DDD Q36191443-D34B785E-5896-40A1-B65E-F4A9BB1A0326 Q36274386-E8520280-3767-4F47-98EB-CA68FD594B7C Q36407018-AAD499A3-EA09-4342-A30B-D9653D897797 Q37620470-6F65E188-8C02-4CC8-99D7-66165C592DDC Q37671783-4D48B2E3-DFDC-416A-82AE-BB11E1CA80D7 Q38203354-17AD20DF-75E8-4C51-9517-A5A37DCD485B Q38222517-6FD5187C-78A8-4167-8F64-B0AE01906510 Q38261469-C210C1A0-59D8-40CD-8952-50AF611835D5 Q38656675-79C9DF68-A871-44C2-8038-E90CCC979BAF Q38753038-CBFCA4C6-6957-4C35-961F-EE919E6643A0 Q38895754-E295B895-17FC-4094-B9AF-313BA630AAC3 Q39026766-6A4C2597-2EED-468A-9250-10726B662F67 Q47103210-1293E2D0-2B8B-413A-9368-26F1A491BF32 Q47796770-2137C5CB-210A-4E49-A686-FC1AAB963FC5 Q53322874-68FDBCBF-0D90-43EC-801B-B59F5D9DAEFC Q53322899-FE13C54D-7A61-4652-9C4B-87D2768DA712 Q54977789-72D56D33-D998-480F-95D6-FCD27AE615E9

P2860

A phase II evaluation of gefitinib in the treatment of persistent or recurrent endometrial cancer: a Gynecologic Oncology Group study

http://www.wikidata.org/entity/Q36980484

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

A phase II evaluation of gefit ...... necologic Oncology Group study

@en

type

label

A phase II evaluation of gefit ...... necologic Oncology Group study

@en

prefLabel

A phase II evaluation of gefit ...... necologic Oncology Group study

@en

P1433

Q36980484-27BD27AC-0EC7-433E-87C6-928F68B42DC9

P1476

Q36980484-4A31001A-DCE8-45CD-B6A3-FEFA921DA5DD

P2093

Q36980484-066DBAF2-88E3-4AFF-9EBC-253E35423A09

Q36980484-2B07D13E-23F5-4FBA-8A0E-48A8B4F3084E

Q36980484-4254AF6C-454A-44BC-9C38-61ED388B9EA3

Q36980484-82574B4E-005C-4FEC-9F28-74B744BEFD54

Q36980484-9281E00B-887A-454D-8F5A-F1F5FF638C6B

Q36980484-9AF4F611-19B0-4BAD-A63D-BF7BDD151226

Q36980484-B044D4FA-B27B-4068-906F-5C9EB4043551

Q36980484-D2D97ED6-874F-4CEE-BB34-5AAF77A14663

Q36980484-D6E19732-8CDD-4168-8666-46E1392C187D

Q36980484-E40E8CBE-220C-4442-BEAA-C3BCB42EDC1F

P2860

Q36980484-11E3A44D-28B3-4AE8-82FF-EF1CC22EA820

Q36980484-168A94FE-6540-4C9A-A1F7-E0EDAC514E1C

Q36980484-1F9D8AD9-BCC9-478B-B205-C03378AB481B

Q36980484-24D842DA-F129-40AA-BC3F-3BEA51161364

Q36980484-2CEA27F5-BC45-4E79-8BB0-B54B12C6ED6C

Q36980484-3313D5AB-35EE-45E1-AC63-6A5F20856AF3

Q36980484-3AD6D01E-319C-4E4A-9EDC-713E37A4F5BE

Q36980484-407C30E5-1ED2-4F2C-808E-6086A22CE015

Q36980484-466FC864-EEE7-4745-891F-4D6486A2E5C0

Q36980484-488CEA31-ECEE-4C74-A2DA-2CDE3AD11936

P304

Q36980484-DB8BC122-B775-478D-B97B-C4EA59DC1901

P31

Q36980484-3BDA24A4-F076-4E11-B101-1F622A1E74AF

P356

Q36980484-8B72B4F5-9701-4A65-A98A-F16D1CD44D87

P407

Q36980484-9FE22D8B-9E62-4E23-A2E9-015D45C4B9FE

P433

Q36980484-B28939E8-4067-47BF-928B-13E6D57A6025

P478

Q36980484-F1DA3702-4BF2-4EBC-A4CF-F318D8D83A36

P50

Q36980484-62F15B5B-C616-4DF7-AB84-57C5CA0775BD

Q36980484-703F818E-2744-4990-811A-BEDDD99C5FB9

P577

Q36980484-1D16AD43-BA2B-4B60-9776-B9F5E5BC4DA8

P5875

Q36980484-C8DFCABA-20EC-4B05-95E2-5F32C6090D05

P698

Q36980484-21FBB0B3-7A84-4C34-981E-BEFDB9E17F90

P932

Q36980484-8A65437E-D4DE-4AB3-B6E8-5E7298312A9A

P356

J.YGYNO.2013.02.019

P1433

Gynecologic Oncology

P1476

A phase II evaluation of gefit ...... necologic Oncology Group study

@en

P2093

Andrew K Godwin

http://www.w3.org/2001/XMLSchema#string

Edgar Fischer

http://www.w3.org/2001/XMLSchema#string

Jason A Wilken

http://www.w3.org/2001/XMLSchema#string

Kathleen M Darcy

http://www.w3.org/2001/XMLSchema#string

Krishnansu S Tewari

http://www.w3.org/2001/XMLSchema#string

Meenakshi Singh

http://www.w3.org/2001/XMLSchema#string

Michael W Sill

http://www.w3.org/2001/XMLSchema#string

Nita J Maihle

http://www.w3.org/2001/XMLSchema#string

Parviz Hanjani

http://www.w3.org/2001/XMLSchema#string

Robert S Mannel

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2012

ERBB receptors and cancer: the complexity of targeted inhibitors

Inhibition of nuclear receptor signalling by poly(ADP-ribose) polymerase.

EGFR isoforms and gene regulation in human endometrial cancer cells

Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies.

Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer.

EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.

HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer.

Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer.

Identification of immunoreactive regions of homology between soluble epidermal growth factor receptor and α5-integrin

P304

486-494

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.YGYNO.2013.02.019

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

129

http://www.w3.org/2001/XMLSchema#string

P50

Kimberly K Leslie

P577

2013-02-21T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

256925372

http://www.w3.org/2001/XMLSchema#string

P698

23438670

http://www.w3.org/2001/XMLSchema#string

P932

3700732

http://www.w3.org/2001/XMLSchema#string